Shigeo Shimose

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Journal: Clinical nutrition ESPEN

Published: June 13, 2026

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Journal: JHEP reports : innovation in hepatology

Published: March 27, 2026

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 07, 2026

Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 20, 2026

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 03, 2025

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

Journal: Internal medicine (Tokyo, Japan)

Published: October 15, 2025

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.

Journal: Journal of liver cancer

Published: September 25, 2025

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 13, 2025

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 13, 2025

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: June 06, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 27, 2025

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Journal of gastroenterology and hepatology

Published: May 18, 2025

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Atezolizumab-Bevacizumab with or without Cisplatin-based HAIC for Unresectable HCC: A Randomized Phase 2 Trial.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt.

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.

Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib.

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.